WAM
DNLI icon

Wolverine Asset Management’s Denali Therapeutics DNLI Stock Holding History

Wolverine Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,966
Closed -$249K – 1467
2017
Q4 		$249K Buy
+15,966
New +$287K ﹤0.01% 1051

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Wolverine Asset Management's DNLI Position: Q1 2018 in Review

Wolverine Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 15,966 shares — an estimated $249K sold.

Wolverine Asset Management first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $249K in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

  • Wolverine Asset Management reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Wolverine Asset Management sold 15,966 Denali Therapeutics shares in Q1 2018, an estimated $249K.
  • Wolverine Asset Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
  • Wolverine Asset Management's Denali Therapeutics position peaked at $249K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on Wolverine Asset Management's 13F filing for Q1 2018, filed 15 May 2018.